Literature DB >> 25332962

Real-time liquid biopsy: circulating tumor cells versus circulating tumor DNA.

Catherine Alix-Panabières1, Klaus Pantel1.   

Abstract

Liquid biopsy is a new diagnostic concept, i.e., analysis of therapeutic targets and drug resistance-conferring gene mutations on circulating tumor cells and cell-free circulating tumor DNA released into the peripheral blood from metastatic deposits. Here, we discuss current challenges and future perspectives of the liquid biopsy concept in clinical oncology. We postulate that this concept will contribute to a better understanding and clinical management of drug resistance in cancer patients.

Entities:  

Keywords:  Cancer; biomarkers; blood; circulating tumor DNA (ctDNA); circulating tumor cells (CTCs); therapy

Year:  2013        PMID： 25332962      PMCID： PMC4200637          DOI： 10.3978/j.issn.2305-5839.2013.06.02

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


  12 in total

Review 1.  Cell-free nucleic acids as biomarkers in cancer patients.

Authors:  Heidi Schwarzenbach; Dave S B Hoon; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2011-05-12       Impact factor: 60.716

Review 2.  Circulating tumor cells: liquid biopsy of cancer.

Authors:  Catherine Alix-Panabières; Klaus Pantel
Journal:  Clin Chem       Date:  2012-09-26       Impact factor: 8.327

3.  Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer.

Authors:  Heidi Schwarzenbach; Catherine Alix-Panabières; Imke Müller; Nicolas Letang; Jean-Pierre Vendrell; Xavier Rebillard; Klaus Pantel
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

4.  Analysis of circulating tumor DNA to monitor metastatic breast cancer.

Authors:  Sarah-Jane Dawson; Dana W Y Tsui; Muhammed Murtaza; Heather Biggs; Oscar M Rueda; Suet-Feung Chin; Mark J Dunning; Davina Gale; Tim Forshew; Betania Mahler-Araujo; Sabrina Rajan; Sean Humphray; Jennifer Becq; David Halsall; Matthew Wallis; David Bentley; Carlos Caldas; Nitzan Rosenfeld
Journal:  N Engl J Med       Date:  2013-03-13       Impact factor: 91.245

5.  Capture of viable circulating tumor cells in the liver of colorectal cancer patients.

Authors:  Eric Denève; Sabine Riethdorf; Jeanne Ramos; David Nocca; Amandine Coffy; Jean-Pierre Daurès; Thierry Maudelonde; Jean-Michel Fabre; Klaus Pantel; Catherine Alix-Panabières
Journal:  Clin Chem       Date:  2013-05-21       Impact factor: 8.327

6.  Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.

Authors:  Christin Gasch; Thomas Bauernhofer; Martin Pichler; Sabine Langer-Freitag; Matthias Reeh; Adrian M Seifert; Oliver Mauermann; Jakob R Izbicki; Klaus Pantel; Sabine Riethdorf
Journal:  Clin Chem       Date:  2012-11-07       Impact factor: 8.327

7.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

8.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.

Authors:  Luis A Diaz; Richard T Williams; Jian Wu; Isaac Kinde; J Randolph Hecht; Jordan Berlin; Benjamin Allen; Ivana Bozic; Johannes G Reiter; Martin A Nowak; Kenneth W Kinzler; Kelly S Oliner; Bert Vogelstein
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

9.  Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing.

Authors:  Ellen Heitzer; Martina Auer; Christin Gasch; Martin Pichler; Peter Ulz; Eva Maria Hoffmann; Sigurd Lax; Julie Waldispuehl-Geigl; Oliver Mauermann; Carolin Lackner; Gerald Höfler; Florian Eisner; Heinz Sill; Hellmut Samonigg; Klaus Pantel; Sabine Riethdorf; Thomas Bauernhofer; Jochen B Geigl; Michael R Speicher
Journal:  Cancer Res       Date:  2013-03-07       Impact factor: 12.701

10.  Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer.

Authors:  Ellen Heitzer; Martina Auer; Eva Maria Hoffmann; Martin Pichler; Christin Gasch; Peter Ulz; Sigurd Lax; Julie Waldispuehl-Geigl; Oliver Mauermann; Sumitra Mohan; Gunda Pristauz; Carolin Lackner; Gerald Höfler; Florian Eisner; Edgar Petru; Heinz Sill; Hellmut Samonigg; Klaus Pantel; Sabine Riethdorf; Thomas Bauernhofer; Jochen B Geigl; Michael R Speicher
Journal:  Int J Cancer       Date:  2013-02-13       Impact factor: 7.396
View more
  16 in total

1.  Image-Guided Biopsy in the Era of Personalized Cancer Care: Proceedings from the Society of Interventional Radiology Research Consensus Panel.

Authors:  Alda L Tam; Howard J Lim; Ignacio I Wistuba; Anobel Tamrazi; Michael D Kuo; Etay Ziv; Stephen Wong; Albert J Shih; Robert J Webster; Gregory S Fischer; Sunitha Nagrath; Suzanne E Davis; Sarah B White; Kamran Ahrar
Journal:  J Vasc Interv Radiol       Date:  2015-11-25       Impact factor: 3.464

Review 2.  Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring.

Authors:  David Pérez-Callejo; Atocha Romero; Mariano Provencio; María Torrente
Journal:  Transl Lung Cancer Res       Date:  2016-10

3.  Improving accuracy of diagnostic studies in a world with limited resources: a road ahead.

Authors:  Giuseppe Lippi; Mario Plebani
Journal:  Ann Transl Med       Date:  2016-02

Review 4.  Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma.

Authors:  Jian Zhou; Ao Huang; Xin-Rong Yang
Journal:  J Gastrointest Cancer       Date:  2016-06

5.  Molecular pathology testing for non-small cell lung cancer: an observational study of elements currently present in request forms and result reports and the opinion of different stakeholders.

Authors:  Kelly Dufraing; Kaat Van Casteren; Joke Breyne; Nicky D'Haene; Claude Van Campenhout; Sara Vander Borght; Karen Zwaenepoel; Etienne Rouleau; Ed Schuuring; Jan von der Thüsen; Elisabeth Dequeker
Journal:  BMC Cancer       Date:  2022-07-06       Impact factor: 4.638

Review 6.  Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.

Authors:  Andrea Ravelli; James M Reuben; Francesco Lanza; Simone Anfossi; Maria Rosa Cappelletti; Laura Zanotti; Angela Gobbi; Chiara Senti; Paola Brambilla; Manuela Milani; Daniele Spada; Paolo Pedrazzoli; Massimo Martino; Alberto Bottini; Daniele Generali
Journal:  Tumour Biol       Date:  2015-08-26

7.  Liquid biopsies in bladder cancer-did we find the Holy Grail for biomarker analyses?

Authors:  Michael Rink; Shahrokh F Shariat; Armin Soave
Journal:  Transl Androl Urol       Date:  2016-12

Review 8.  Emerging proteomics biomarkers and prostate cancer burden in Africa.

Authors:  Henry A Adeola; Jonathan M Blackburn; Timothy R Rebbeck; Luiz F Zerbini
Journal:  Oncotarget       Date:  2017-06-06

Review 9.  The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer.

Authors:  Sabine Riethdorf; Armin Soave; Michael Rink
Journal:  Transl Androl Urol       Date:  2017-12

Review 10.  Circulating tumor cells in breast cancer.

Authors:  Francois-Clement Bidard; Charlotte Proudhon; Jean-Yves Pierga
Journal:  Mol Oncol       Date:  2016-01-12       Impact factor: 6.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.